The General
Footballguy
Would people buy some GD meatless burgers and help a brother out? BYND needs you.
They were discussing the Cytokyn Storm atleast a month before anyone else.They’re as far into trials for Covid therapeutics as almost anyone. Their MOA makes sense, no?
What’s bearish?
Yeah, the prudent thing to do would be sell another 1/3 to make sure that if this does go up the creek that I won't end up losing my buy in on all my buying and selling of it. I feel like there's a 30-40-% chance for this to moon, 60-70% to crater. The thing that puts the fly into the ointment is my intuition on stocks is wrong about 80% of the time.It’s about 9% of mine right now but half of that is profit. My cost is right is about 4%. I may trim end of day as it tends to pop lately close to the end of the day. I’m not sure if I can sell half and know that I’m free rolling because I’d hate to miss out on a huge gain but damn it would suck to make nothing on it at this point.
Guys I’m starting to think we are going to get rich. Are we going to get rich?$6.03! Someone on the boards said there was a massive buy of 250,000 shares.
I'm not because I got in late. I'm just hopeful to learns some things and make a little money if possible. Either way I'm holding.Guys I’m starting to think we are going to get rich. Are we going to get rich?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157023909
Newly announced CytoDyn Scientific Advisory Board member Dr. Hope S. Rugo will be featured on Research To Practice tonight:
Recent Advances in Medical Oncology:
Focus on Triple-Negative Breast Cancer
Part 6 of a 14-Part CME Webinar Series Held in
Conjunction with ASCO20 Virtual
Monday, July 20 — 5:00 PM - 6:00 PM ET
Access Tonight's Webinar: https://us02web.zoom.us/webinar/register/WN_olnKrJvGQg2eBvm0prFz7w
Our summer webinar series held in partnership with the American Society of Clinical Oncology continues tonight at 5 PM ET as Drs Joyce O’Shaughnessy and Hope S Rugo join me to share their perspectives on optimal targeted treatment approaches for patients with triple-negative breast cancer and touch on how the COVID-19 pandemic has affected the delivery of cancer care.///
Happens with all melt ups. Two steps forward, one step back. I think we end at $6.50+ today.Now falling
Not good IMO.https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157023909
Newly announced CytoDyn Scientific Advisory Board member Dr. Hope S. Rugo will be featured on Research To Practice tonight:
Recent Advances in Medical Oncology:
Focus on Triple-Negative Breast Cancer
Part 6 of a 14-Part CME Webinar Series Held in
Conjunction with ASCO20 Virtual
Monday, July 20 — 5:00 PM - 6:00 PM ET
Access Tonight's Webinar: https://us02web.zoom.us/webinar/register/WN_olnKrJvGQg2eBvm0prFz7w
Our summer webinar series held in partnership with the American Society of Clinical Oncology continues tonight at 5 PM ET as Drs Joyce O’Shaughnessy and Hope S Rugo join me to share their perspectives on optimal targeted treatment approaches for patients with triple-negative breast cancer and touch on how the COVID-19 pandemic has affected the delivery of cancer care.///
What am I missing here? That she is discussing cancer and not corona? Maybe that’s just her lane.It is curious to say the least.
Agree. It's not related to Covid or the Covid trial data. It's focusing on triple-negative breast cancer and some how Covid has distracted focus from cancer care. It's good for down the road indication of cancer.Why?
Why would you be pimping an alternate use on the day or day before your COVID release? This appears like the COVID data was the suck and they are moving on to the next shiny thing.Why?
Correct. And newly appointed. She may not even be involved with the Covid related research.What am I missing here? That she is discussing cancer and not corona? Maybe that’s just her lane.
Right.Why would you be pimping an alternate use on the day or day before your COVID release? This appears like the COVID data was the suck and they are moving on to the next shiny thing.
Agree, why discuss cancer when your Covid results are front and center?Why would you be pimping an alternate use on the day or day before your COVID release? This appears like the COVID data was the suck and they are moving on to the next shiny thing.
It was already scheduled as part of a 14 part series.Why would you be pimping an alternate use on the day or day before your COVID release? This appears like the COVID data was the suck and they are moving on to the next shiny thing.
This would be like Santa pulling all the kids aside on December 24th to discuss how fat the the turkeys are looking for next year.What am I missing here? That she is discussing cancer and not corona? Maybe that’s just her lane.
covid-19 isn't their only area of focus. I don't see this as bad at all.Agree, why discuss cancer when your Covid results are front and center?
Not if there were 7 Santas though and one of them was focused on fat turkeys.This would be like Santa pulling all the kids aside on December 24th to discuss how fat the the turkeys are looking for next year.
This. Everyone take a deep breath..... unless you have corona.... which this is going to help with.I get we’re all paranoid but this is stretching the boundaries of it lol
If their Covid results are the suck, our investment falls at a minimum 50%, maybe upwards of 80-90%.covid-19 isn't their only area of focus. I don't see this as bad at all.
I’m not sure I agree. Cancer and HIV was always the main driver of the company. Covid is the recent development. But they should still be focused on what was always the long-term goal.Why would you be pimping an alternate use on the day or day before your COVID release? This appears like the COVID data was the suck and they are moving on to the next shiny thing.
If it was scheduled in advance, I’m okay with it.It was already scheduled as part of a 14 part series.
Because it is and always was the focus of this drug.Agree, why discuss cancer when your Covid results are front and center?
Well sure. I get that. But this webinar was already scheduled and she has nothing to do with the covid trials or the data. Non sequitur.If their Covid results are the suck, our investment falls at a minimum 50%, maybe upwards of 80-90%.
That’s the bottom line.
I thought we covered this. It cures erectile dysfunction, male pattern baldness and grumpy wife syndromeI’m not sure I agree. Cancer and HIV was always the main driver of the company. Covid is the recent development. But they should still be focused on what was always the long-term goal.